Patent ID: 8090562
Filing Date: 2012-01-03
Classification: C12Q,G01N,G16H

Abstract:
1. A method for evaluating a subject's risk of a major adverse cardiac event (MACE) within one year, the method comprising: determining a first level of soluble Growth Stimulation-Expressed Gene 2 (ST2) in a biological sample obtained from a subject at a first time point (ST2T0), a second level of soluble ST2 in a biological sample obtained from a subject at a second time point (ST2T1), and a level of natriuretic peptide (NP) in a biological sample obtained from a subject at the second time point (NPT1); determining a MACE risk score (MACERS) for a subject utilizing, at least in part, a ratio of ST2T1 to ST2T0, in combination with a weighted logarithm of NPT1, and comparing the MACERS to a reference MACERS; wherein the MACERS in comparison with the reference MACERS is indicative of the subject's risk of a MACE within one year.